1/28
08:41 am
cbll
CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $30.00 price target on the stock.
Medium
Report
CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $30.00 price target on the stock.
1/14
09:41 am
cbll
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion [Yahoo! Finance]
Low
Report
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion [Yahoo! Finance]
1/5
08:40 am
cbll
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution [Yahoo! Finance]
High
Report
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution [Yahoo! Finance]
1/5
08:00 am
cbll
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Medium
Report
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
12/30
04:05 pm
cbll
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/17
03:07 pm
cbll
CeriBell (NASDAQ:CBLL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $29.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
CeriBell (NASDAQ:CBLL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $29.00 to $30.00. They now have a "buy" rating on the stock.
12/15
07:20 am
cbll
CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at BTIG Research.
Medium
Report
CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at BTIG Research.
12/12
09:49 am
cbll
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
Low
Report
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
12/9
12:17 pm
cbll
CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
CeriBell (NASDAQ:CBLL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/9
08:00 am
cbll
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
Low
Report
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
11/24
08:00 am
cbll
Ceribell Receives FDA 510(k) Clearance for Use of Clarity? Algorithm for Neonates
Medium
Report
Ceribell Receives FDA 510(k) Clearance for Use of Clarity? Algorithm for Neonates
11/19
04:05 pm
cbll
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference